Indian pharma player Wockhardt Ltd has said that the Phase III clinical trial for Zaynich (Zidebactam/Cefepime) is making progress according to the schedule and is likely to complete by the first quarter of 2025.
Zidebactam/Cefepime, an investigational antibiotic categorised under the novel class of ‘β-lactam enhancers’, is under evaluation for its efficacy in treating complicated urinary tract infections, including acute pyelonephritis. The trial, as of May 27, has successfully enrolled 392 patients, the company said in a press statement.
